The key factors that are driving growth of the market are increasing demand for third generation sequencing along with growing funding for pharmacogenomic research activities. However, the dearth of skilled professionals is expected to restrict the market growth during the forecast period.
The development of newer and better DNA sequencing technologies has led to over a thousand-fold decrease in the cost of sequencing genomes since the launch of the Human Genome Project. The third generation of sequencing underwent development after the next-generation sequencing reached the market. Genomic sequencing technologies have revolutionized mutation detection of genetic diseases in the past few years. The third-generation sequencing (TGS) has gained insight into more genetic disorders due to the single molecular and real-time sequencing technology.
Pacific Biosciences developed new technologies called Single-Molecule Sequencing in Real-Time (SMRT). SMRT is efficient and uses fewer expensive chemicals. Its high sensitivity enables scientists to effectively observe DNA polymerase and watch it make a strand of DNA.
A rise in the demand for third-generation sequencing (TGS) technologies is attributive to the lucrative growth rate of radiation dose management segment. With the emergence of TGS, genome sequencing has become a faster and more reliable method to study genomic variations. SMRT technology has allowed scientists to initiate re-sequencing of the sequenced genome to obtain higher accuracy. Escherichia coli is sequenced to an accuracy of 99.99% by using the SMRT technique.
Third-generation long-range DNA sequencing and mapping technologies are resulting in high-quality genome sequencing. Unlike second-generation sequencing, which produces short reads over a few hundred base-pairs, third-generation single-molecule technologies generate over 10,000 bp reads or map over 100,000 bp molecules.
| Report Attribute | Details |
|---|---|
| Market size in 2021 | US$ 225.72 Million |
| Market Size by 2028 | US$ 427.68 Million |
| CAGR (2021 - 2028) | 9.6% |
| Historical Data | 2019-2020 |
| Forecast period | 2022-2028 |
| Segments Covered |
By Technology
|
| Regions and Countries Covered |
Middle East and Africa
|
| Market leaders and key company profiles |
|
The Middle East and Africa Pharmacogenomics Market is valued at US$ 225.72 Million in 2021, it is projected to reach US$ 427.68 Million by 2028.
As per our report Middle East and Africa Pharmacogenomics Market, the market size is valued at US$ 225.72 Million in 2021, projecting it to reach US$ 427.68 Million by 2028. This translates to a CAGR of approximately 9.6% during the forecast period.
The Middle East and Africa Pharmacogenomics Market report typically cover these key segments-
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the Middle East and Africa Pharmacogenomics Market report:
The Middle East and Africa Pharmacogenomics Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
The Middle East and Africa Pharmacogenomics Market report is valuable for diverse stakeholders, including:
Essentially, anyone involved in or considering involvement in the Middle East and Africa Pharmacogenomics Market value chain can benefit from the information contained in a comprehensive market report.
Please tell us your area of interest
(Market Segments/ Regions and Countries/ Companies)
E 1803, Panchshil Towers,
Wagholi, Haveli,
Pune - 412207,
Maharashtra, India
US:+16467917070
sales@businessmarketinsights.com
Get Free Sample For Middle East and Africa Pharmacogenomics Market
